Toll Free: 1-888-928-9744

Women Infertility - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 209 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Women Infertility - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2015', provides an overview of the Women Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Women Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Women Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Women Infertility Overview 10 Therapeutics Development 11 Pipeline Products for Women Infertility - Overview 11 Pipeline Products for Women Infertility - Comparative Analysis 12 Women Infertility - Therapeutics under Development by Companies 13 Women Infertility - Therapeutics under Investigation by Universities/Institutes 17 Women Infertility - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Women Infertility - Products under Development by Companies 22 Women Infertility - Products under Investigation by Universities/Institutes 27 Women Infertility - Companies Involved in Therapeutics Development 28 AbbVie Inc. 28 Addex Therapeutics Ltd 29 Allergan Plc 30 AlphaMab Co., Ltd 31 APAvadis Biotechnologies Srl 32 ASKA Pharmaceutical Co., Ltd. 33 Astellas Pharma Inc. 34 Bayer AG 35 BIOCAD 36 Dong-A Socio Group 37 Dongkook Pharmaceutical Co., Ltd. 38 ElexoPharm GmbH 39 EndoCeutics, Inc. 40 Enteris BioPharma, Inc. 41 Euroscreen S.A. 42 Evotec AG 43 Ferring International Center S.A. 44 Finox AG 45 Forendo Pharma Limited 46 GlaxoSmithKline Plc 47 Glycotope GmbH 48 Kissei Pharmaceutical Co., Ltd. 49 Lipicard Technologies Limited 50 Merrion Pharmaceuticals Plc 51 Nippon Shinyaku Co., Ltd. 52 Nora Therapeutics, Inc. 53 ObsEva SA 54 Orphagen Pharmaceuticals, Inc. 55 Pantec Biosolutions AG 56 PharmaEssentia Corporation 57 Philogen S.p.A. 58 Reliance Life Sciences Pvt. Ltd. 59 Repros Therapeutics Inc. 60 SK Chemicals Co., Ltd. 61 Takeda Pharmaceutical Company Limited 62 TocopheRx, Inc. 63 Trophogen, Inc. 64 ValiRx Plc 65 Viteava Pharmaceuticals, Inc. 66 Zydus Cadila Healthcare Limited 67 Women Infertility - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Combination Products 69 Assessment by Target 70 Assessment by Mechanism of Action 73 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 80 (anastrozole + levonorgestrel) - Drug Profile 80 acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 81 AKP-501 - Drug Profile 82 ASP-1707 - Drug Profile 83 barusiban - Drug Profile 84 BAY-1128688 - Drug Profile 85 bentamapimod - Drug Profile 86 Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile 87 Biosimilar 5 for Infertility - Drug Profile 88 Biosimilar 6 for Infertility - Drug Profile 89 Biosimilar 7 for Infertility and Oncology - Drug Profile 90 choriogonadotropin alfa - Drug Profile 91 DKF-301 - Drug Profile 92 DKF-304 - Drug Profile 93 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 94 Drugs for Endometriosis - Drug Profile 95 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 96 elagolix sodium - Drug Profile 97 epelsiban besylate - Drug Profile 99 ESN-364 - Drug Profile 101 EVE-104 - Drug Profile 103 FE-999310 - Drug Profile 104 follitropin alfa - Drug Profile 105 follitropin alfa - Drug Profile 107 follitropin alfa - Drug Profile 108 follitropin alfa (recombinant) - Drug Profile 109 follitropin delta - Drug Profile 110 FP-5677 - Drug Profile 111 FSH-GEX - Drug Profile 112 kisspeptin-54 - Drug Profile 114 KLH-2109 - Drug Profile 115 KN-015 - Drug Profile 116 leuprolide acetate - Drug Profile 117 LM-001 - Drug Profile 118 LM-002 - Drug Profile 119 LT-6121 - Drug Profile 120 menotropins - Drug Profile 121 MER-104 - Drug Profile 122 MIA-602 - Drug Profile 124 Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile 126 Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 127 NCE-403 - Drug Profile 128 NS-580 - Drug Profile 129 NT-100 - Drug Profile 130 OBE-001 - Drug Profile 131 PEG-FSH - Drug Profile 132 Peptides for Cancer and Endometriosis - Drug Profile 133 Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 134 PGL-1001 - Drug Profile 135 PGL-2001 - Drug Profile 136 Progesterone Second Generation - Drug Profile 137 Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 138 Recombinant Protein to Agonize Luteinizing Hormone for Infertility - Drug Profile 139 relugolix - Drug Profile 140 RTPR-013 - Drug Profile 141 S-hCG - Drug Profile 142 SKI-2670 - Drug Profile 143 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 144 Small Molecules for Female Infertility - Drug Profile 145 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 146 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 147 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 148 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 149 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 150 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 151 SR-16234 - Drug Profile 152 STI-2833 - Drug Profile 153 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 154 telapristone acetate - Drug Profile 155 Tetravil - Drug Profile 158 TOP-001 - Drug Profile 160 TOP-002 - Drug Profile 161 TR-4401 - Drug Profile 162 triptorelin - Drug Profile 163 VAL-201 - Drug Profile 164 vilaprisan - Drug Profile 166 VPE-001 - Drug Profile 167 VPEA-004 - Drug Profile 168 Women Infertility - Recent Pipeline Updates 169 Women Infertility - Dormant Projects 188 Women Infertility - Discontinued Products 192 Women Infertility - Product Development Milestones 194 Featured News & Press Releases 194 Appendix 202 Methodology 202 Coverage 202 Secondary Research 202 Primary Research 202 Expert Panel Validation 202 Contact Us 202 Disclaimer 203
List of Tables
Number of Products under Development for Women Infertility, H2 2015 17 Number of Products under Development for Women Infertility - Comparative Analysis, H2 2015 18 Number of Products under Development by Companies, H2 2015 20 Number of Products under Development by Companies, H2 2015 (Contd..1) 21 Number of Products under Development by Companies, H2 2015 (Contd..2) 22 Number of Products under Investigation by Universities/Institutes, H2 2015 23 Comparative Analysis by Late Stage Development, H2 2015 24 Comparative Analysis by Clinical Stage Development, H2 2015 25 Comparative Analysis by Early Stage Development, H2 2015 26 Comparative Analysis by Unknown Stage Development, H2 2015 27 Products under Development by Companies, H2 2015 28 Products under Development by Companies, H2 2015 (Contd..1) 29 Products under Development by Companies, H2 2015 (Contd..2) 30 Products under Development by Companies, H2 2015 (Contd..3) 31 Products under Development by Companies, H2 2015 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2015 33 Women Infertility - Pipeline by AbbVie Inc., H2 2015 34 Women Infertility - Pipeline by Addex Therapeutics Ltd, H2 2015 35 Women Infertility - Pipeline by Allergan Plc, H2 2015 36 Women Infertility - Pipeline by AlphaMab Co., Ltd, H2 2015 37 Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H2 2015 38 Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2015 39 Women Infertility - Pipeline by Astellas Pharma Inc., H2 2015 40 Women Infertility - Pipeline by Bayer AG, H2 2015 41 Women Infertility - Pipeline by BIOCAD, H2 2015 42 Women Infertility - Pipeline by Dong-A Socio Group, H2 2015 43 Women Infertility - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 44 Women Infertility - Pipeline by ElexoPharm GmbH, H2 2015 45 Women Infertility - Pipeline by EndoCeutics, Inc., H2 2015 46 Women Infertility - Pipeline by Enteris BioPharma, Inc., H2 2015 47 Women Infertility - Pipeline by Euroscreen S.A., H2 2015 48 Women Infertility - Pipeline by Evotec AG, H2 2015 49 Women Infertility - Pipeline by Ferring International Center S.A., H2 2015 50 Women Infertility - Pipeline by Finox AG, H2 2015 51 Women Infertility - Pipeline by Forendo Pharma Limited, H2 2015 52 Women Infertility - Pipeline by GlaxoSmithKline Plc, H2 2015 53 Women Infertility - Pipeline by Glycotope GmbH, H2 2015 54 Women Infertility - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 55 Women Infertility - Pipeline by Lipicard Technologies Limited, H2 2015 56 Women Infertility - Pipeline by Merrion Pharmaceuticals Plc, H2 2015 57 Women Infertility - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 58 Women Infertility - Pipeline by Nora Therapeutics, Inc., H2 2015 59 Women Infertility - Pipeline by ObsEva SA, H2 2015 60 Women Infertility - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 61 Women Infertility - Pipeline by Pantec Biosolutions AG, H2 2015 62 Women Infertility - Pipeline by PharmaEssentia Corporation, H2 2015 63 Women Infertility - Pipeline by Philogen S.p.A., H2 2015 64 Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015 65 Women Infertility - Pipeline by Repros Therapeutics Inc., H2 2015 66 Women Infertility - Pipeline by SK Chemicals Co., Ltd., H2 2015 67 Women Infertility - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 68 Women Infertility - Pipeline by TocopheRx, Inc., H2 2015 69 Women Infertility - Pipeline by Trophogen, Inc., H2 2015 70 Women Infertility - Pipeline by ValiRx Plc, H2 2015 71 Women Infertility - Pipeline by Viteava Pharmaceuticals, Inc., H2 2015 72 Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 73 Assessment by Monotherapy Products, H2 2015 74 Assessment by Combination Products, H2 2015 75 Number of Products by Stage and Target, H2 2015 77 Number of Products by Stage and Mechanism of Action, H2 2015 80 Number of Products by Stage and Route of Administration, H2 2015 83 Number of Products by Stage and Molecule Type, H2 2015 85 Women Infertility Therapeutics - Recent Pipeline Updates, H2 2015 175 Women Infertility - Dormant Projects, H2 2015 194 Women Infertility - Dormant Projects (Contd..1), H2 2015 195 Women Infertility - Dormant Projects (Contd..2), H2 2015 196 Women Infertility - Dormant Projects (Contd..3), H2 2015 197 Women Infertility - Discontinued Products, H2 2015 198 Women Infertility - Discontinued Products (Contd..1), H2 2015 199



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify